During the past decade, Centre Hospitalier Regional de Lanaudiere conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 4 clinical trials were completed, i.e. on average, 133.3% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 2 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Centre Hospitalier Regional de Lanaudiere" #1 sponsor was "NCIC Clinical Trials Group" with 4 trials, followed by "Montreal Heart Institute" with 2 trials sponsored, "Pfizer" with 2 trials sponsored, "AGO Study Group" with 1 trials sponsored and "Alliance for Clinical Trials in Oncology" with 1 trials sponsored. Other sponsors include 1 different institutions and companies that sponsored additional 11 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Centre Hospitalier Regional de Lanaudiere" #1 collaborator was "NCIC Clinical Trials Group" with 4 trials as a collaborator, "National Cancer Institute (NCI)" with 3 trials as a collaborator, "Canadian Institutes of Health Research (CIHR)" with 2 trials as a collaborator, "Amgen" with 1 trials as a collaborator and "Boston VA Research Institute, Inc." with 1 trials as a collaborator. Other collaborators include 15 different institutions and companies that were collaborators in the rest 25 trials.

According to Clinical.Site data, the most researched conditions in "Centre Hospitalier Regional de Lanaudiere" are "Cardiovascular Disease" (3 trials), "Ovarian Cancer" (2 trials), "Atherosclerosis" (1 trials), "Bladder Cancer" (1 trials) and "Breast Cancer" (1 trials). Many other conditions were trialed in "Centre Hospitalier Regional de Lanaudiere" in a lesser frequency.

Most popular intervention types in "Centre Hospitalier Regional de Lanaudiere" are "Drug" (10 trials), "Procedure" (2 trials), "Biological" (1 trials), "Genetic" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "alvocidib" (2 trials), "bococizumab (PF-04950615)" (2 trials), "gemcitabine hydrochloride" (2 trials) and "DNA stability analysis" (1 trials). Other intervention names were less common.

The vast majority of trials in "Centre Hospitalier Regional de Lanaudiere" are 13 trials for "All" genders and 3 trials for "Female" genders.

Currently, there are NaN active trials in "Centre Hospitalier Regional de Lanaudiere". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 13 completed trials in Centre Hospitalier Regional de Lanaudiere, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Centre Hospitalier Regional de Lanaudiere, 0 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 2 trials that are defined as “Not Applicable".